Clinical Trial Update: A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports a completed Phase 1/2 study evaluating durvalumab in combination with tremelimumab and SBRT for metastatic cancer, including …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Head and Neck Squamous Cell Carcinoma
• Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Head and Neck Squamous Cell Carcinoma, Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED